ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2017 American Transplant Congress

    Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…
  • 2017 American Transplant Congress

    Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.

    C. Larsen,1 M. Alseiari,2 S. Chandran,2 F. Vincenti,2 D. Wojciechowski.1

    1Division of Nephrology, Massachusetts General Hospital, Boston, MA; 2Division of Nephrology, UCSF, San Francisco, CA

    IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…
  • 2017 American Transplant Congress

    Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.

    M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.

    Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Pediatric Infectious Disease, Johns Hopkins, Baltimore, MD; Pathology, Johns Hopkins, Baltimore, MD

    Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…
  • 2017 American Transplant Congress

    Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients.

    K. Roach, H. Triemer, M. Hurtik, A. Mehta.

    Emory University Hospital, Atlanta, GA

    Purpose: The purpose of this study was to evaluate the timeliness of assessment of positive cytomegalovirus (CMV) polymerase chain reaction (PCR) results. This study served…
  • 2017 American Transplant Congress

    EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.

    C. Durand, D. Brown, R. Wesson, N. Bhair, F. Naqvi, D. Ostrander, M. Bowring, A. Massie, S. Rasmussen, J. Sugarman, D. Segev, M. Sulkowski, N. Desai.

    JHU, Baltimore, MD

    Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…
  • 2017 American Transplant Congress

    Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV).

    P. Baum,1 J. Yao,2 A. Butcher,1 P. Hemyari,1 A. Valsamakis,3 S. Young.4

    1Roche Diagnostics, Pleasanton, CA; 2Mayo, Rochester, MN; 3JHMI, Baltimore, MD; 4Tricore, Albuquerque, NM

    cobas CMV is a new, automated, high-throughput assay for use on the cobas 6800/8800 systems that quantifies CMV DNA in EDTA-plasma. It can be run…
  • 2017 American Transplant Congress

    Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).

    C. Danthu,1 M. Gomes-Mayeras,1 D. Andouard,2 E. Munteanu,1 R. Moulinas,1,4 G. Ligat,2 S. Hantz,1,2 J. Rerolle,3 F. Garnier,1 M. Essig,3 S. Alain.1,2,4

    1National Reference Center for CMV-Virology, CHU Limoges, Limoges, France; 2UMR Inserm 1092, Université Limoges, Limoges, France; 3Nephrology, CHU Limoges, Limoges, France; 4GenoLim/Biscem Genomic Platform, Université Limoges, Limoges, France

    Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…
  • 2017 American Transplant Congress

    Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.

    E. Ko,1,2 J. Yu,1,2 B. Choi,1,2 C. Park,1,2 Y. Kim,1,2 C. Yang,1,2 B. Chung.1,2

    1Transplant Research Center, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea; 2Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

    Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…
  • 2017 American Transplant Congress

    Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.

    Y. Natori,1 A. Alghamdi,1 D. Kumar,1 V. Miller,2 P. Ljungman,3 S. Husain,1 A. Humar.1

    1Multi-Organ Transplant Program, UHN, Toronto, Canada; 2UC-Berkeley, Berkeley; 3Karolinska Inst., Solna, Sweden

    Background: Regulatory trials assessing CMV drugs have utilized symptomatic CMV disease as the primary endpoint. However CMV disease occurs infrequently, CMV syndrome is nonspecific, and…
  • 2017 American Transplant Congress

    Generation of Autologous CMV and EBV-Specific T-Cell Lines from Seronegative Patients for Cell Therapy of Opportunistic Infections Following Kidney Transplantation.

    C. Lamarche,1 T. Pincez,1 J. Orio,1 C. Carli,1 A. Humar,2 J.-S. Delisle.1

    1Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; 2Toronto General Research Institute, Toronto, ON, Canada

    Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations after kidney transplant are associated with substantial morbidity, especially in seronegative patients. Adoptive immunotherapy using virus-specific T cells…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences